821 days ago
OptiBiotix Health (OPTI) was one of our tips of the year, with we anticipating financial progress as its deals for its compounds expand and further deals kick-in. It has now announced that a further human volunteer study on its cholesterol-reducing probiotic LPLDL - on a different population group of hypercholesterolemic adults – has shown “at six weeks, when volunteers taking placebo were compared to those taking LPLDL, there were statistically significant changes to clinically important cardiovascular risk”, including “34.2% reduction in total cholesterol (p=0.001)”.
1291 days ago
OptiBiotix Health (OPTI) is “pleased to see that Seed has achieved FDA authorisation for an IND in a product containing OptiBiotix’s Lactobacillus plantarum LPLDL®”. So, what does this mean?…
1526 days ago
Last week we noted a licencing agreement for LPLDL, of OptiBiotix Health (OPTI), was clearly positive with the potential then significantly added to but that Uruguay itself is clearly not the largest of markets. The latter is not the case for the United States and Canada!…
1531 days ago
OptiBiotix Health (OPTI) has announced “a significant milestone” in extension of the use of its LPLDL probiotic strain into functional foods and its presence into South America. So what you say?
1660 days ago
OptiBiotix Health (OPTI) has updated investors with news including “completing Pharmaceutical GMP process validation and receiving the GRAS notification letter from the US FDA is a significant achievement for ProBiotix and LPLDL®. Few marketed probiotics have achieved this level of proven safety and efficacy and it has triggered another milestone payment in the US Pharmaceutical agreement”…
1811 days ago
Steve O’ Hara says he is looking to do two new distribution deals a month and so here is the first for May. Optibiotix (OPTI) has announced that its fully-owned subsidiary ProBiotix Health Ltd., has signed a license agreement with Instituto Español de Nutrición Personalizada, S.A. for the use of Lactobacillus plantarum (LPLDL) in personalised food supplements in Spain.
1932 days ago
The latest deal from Optibiotix (OPTI) is a three year distribution agreement with a company called SilvEXPO Ltd to distribute and commercialise OptiBiotix's own label CholBiome products containing its cholesterol and blood pressure reducing LPLDL strain in Russia and Kazakhstan.
